Study of BMS-986158 in Subjects With Select Advanced Cancers | NCT02419417

ID	Type	Description	Link
2015-000324-29	EudraCT Number

Study of BMS-986158 in Subjects With Select Advanced Cancers | NCT02419417 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Monotherapy Treatment	Experimental	Patients treated at various doses and schedules	Drug: BMS-986158
Combination Therapy	Experimental	Patients treated at selected doses and schdules	Drug: BMS-986158 Biological: Nivolumab

Name	Type	Description	Arm Group Labels	Other Names
BMS-986158	Drug	Specified dose on specified days	Combination Therapy Monotherapy Treatment

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Number of Participants Experiencing Adverse Events	Number of participants experiencing different types of events, including Adverse Events (AEs), Serious Adverse Events (SAEs), AEs leading to discontinuation and deaths. Events are classified based on the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.	From first dose to 30 days following last dose (up to approximately 29 months)
Number of Participants With Abnormal Hepatic Test Values	Number of participants experiencing abnormal hepatic function, as measured by different parameters. ALT = Alanine aminotransferase AST = Aspartate aminotransferase ULN = Upper Limit of Normal	From first dose to 30 days following last dose (up to approximately 29 months)

Secondary Outcomes

Measure	Description	Time Frame
Best Overall Response (BOR)	BOR, as assessed by the investigator, is defined as the best response designation, recorded between the dates of first dose and the date of first objectively documented progression (per RECIST v1.1 for solid tumors, Lugano 2014 criteria for hematologic malignancies or PCWG3 for prostate cancer) or the date of subsequent therapy, whichever occurs first.	From first dose to date of first documented progression or subsequent therapy (up to approximately 28 months)

Contacts/Locations Module

Name	Affiliation	Role
Bristol-Myers Squibb	Bristol-Myers Squibb	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
City Of Hope National Medical Center		Duarte	California	91010	United States
University Of Colorado

References Module

Label	URL
BMS Clinical Trial Information	View source
BMS Clinical Trial Patient Recruiting	View source
Investigator Inquiry Form

Arm/Group Information

ID	Title	Description
FG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
FG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
FG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
FG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
FG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
FG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
FG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
FG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
FG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
FG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
FG010	Part 2 Schedule A	BMS-986158 administered at 4.5 mg QD for 5 consecutive days, followed by a 2 days resting period, for a total of 10 doses. Then, BMS-986158 is administered at the 3.75 mg dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle

Periods

Title

Milestones

Reasons Not Completed

Overall Study

Type	Comment	Milestone Data
STARTED		FG0005 subjects FG0014 subjects FG00213 subjects FG00310 subjects FG00413 subjects FG0054 subjects FG0064 subjects FG0076 subjects FG00813 subjects FG00910 subjects FG0101 subjects
COMPLETED		FG0000 subjects FG0010 subjects FG0020 subjects FG0030 subjects FG004
NOT COMPLETED		FG0005 subjects FG0014 subjects FG00213 subjects FG00310 subjects FG004

Type	Comment	Reasons
Disease progression		FG0005 subjects FG0014 subjects FG00213 subjects FG003

Baseline Characteristics Module

Arm/Group Information

ID	Title	Description
BG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
BG001	Part 1 Schedule A - BMS-986158 1.25 mg

Units	Counts
Participants	BG000

Baseline Measures

Title	Description	Population Description	Parameter Type	Dispersion Type	Unit of Measure	Calculate Percentage	Denominator Units Selected	Denominators	Classes
Age, Categorical			Count of Participants

Outcome Measures Module

Outcome Measures

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Number of Participants Experiencing Adverse Events

Number of participants experiencing different types of events, including Adverse Events (AEs), Serious Adverse Events (SAEs), AEs leading to discontinuation and deaths.

Events are classified based on the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

All treated participants

Posted

Count of Participants

Participants

From first dose to 30 days following last dose (up to approximately 29 months)

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg

Adverse Events Module

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle

Term	Organ System	Source Vocabulary	Assessment Type	Notes	Statistical Information
Anaemia	Blood and lymphatic system disorders	24.0	Systematic Assessment

Term	Organ System	Source Vocabulary	Assessment Type	Notes	Statistical Information
Anaemia	Blood and lymphatic system disorders	24.0	Systematic Assessment

More Info Module

Certain Agreements

Title	Organization	Phone	Extension	Email
Bristol-Myers Squibb Study Director	Bristol-Myers Squibb	Please email		Clinical.Trials@bms.com

Uploaded Document Information

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot	Yes	No	No	Study Protocol	Mar 18, 2019	Mar 10, 2022	Prot_000.pdf
SAP	No	Yes	No	Statistical Analysis Plan	Aug 23, 2021	Mar 10, 2022	SAP_001.pdf

Intervention Browse Module

ID	Term
D000077594	Nivolumab

ID	Term
D061067	Antibodies, Monoclonal, Humanized
D000911	Antibodies, Monoclonal
D000906	Antibodies
D007136	Immunoglobulins

Title

Denominators

Categories

Title	Measurements
<=18 years	BG0000 BG0010 BG0020 BG0030 BG0040 BG0050 BG0060 BG0070 BG0080 BG0090 BG0100 BG0110
Between 18 and 65 years	BG0004 BG0014 BG0027 BG0037 BG004
>=65 years	BG0001 BG0010 BG0026 BG0033 BG004

Age, Continuous

Mean

Standard Deviation

Years

Title

Denominators

Categories

Title	Measurements
	BG00061.4± 7.2 BG00145.0± 9.4 BG00263.2± 12.1 BG00354.3± 16.4 BG00455.5± 15.4 BG00561.3± 3.0 BG00668.5± 5.4 BG00758.8± 2.7 BG00853.6± 9.1 BG00958.1± 9.9 BG01030.0± NAOnly 1 participant was treated in this arm BG01157.3± 12.2

Sex: Female, Male

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Female	BG0005 BG0013 BG00212 BG0037 BG0049 BG0052 BG0063 BG0075 BG0089 BG0099 BG0100 BG01164
Male	BG0000 BG0011 BG0021 BG0033 BG004

Ethnicity (NIH/OMB)

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Hispanic or Latino	BG0000 BG0010 BG0020 BG0030 BG0040 BG0050 BG0060 BG0071 BG0081 BG0091 BG0100 BG0113
Not Hispanic or Latino	BG0000 BG0011 BG0026 BG0036 BG004
Unknown or Not Reported	BG0005 BG0013 BG0027 BG0034 BG004

Race (NIH/OMB)

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
American Indian or Alaska Native	BG0000 BG0010 BG0020 BG0030 BG0040 BG0050 BG0060 BG0070 BG0080 BG0090 BG0100 BG0110
Asian	BG0000 BG0010 BG0021 BG0030 BG004
Native Hawaiian or Other Pacific Islander	BG0000 BG0010 BG0020 BG0030 BG004
Black or African American	BG0000 BG0011 BG0020 BG0030 BG004
White	BG0005 BG0013 BG00211 BG00310 BG004
More than one race	BG0000 BG0010 BG0020 BG0030 BG004
Unknown or Not Reported	BG0000 BG0010 BG0021 BG0030 BG004

Title

Denominators

Categories

Adverse Events (AEs)

Title	Measurements
	OG0005 OG0014 OG00213 OG00310 OG00413 OG0054 OG0064 OG0076 OG00813 OG0099 OG0101

Serious Adverse Events (SAEs)

Title	Measurements
	OG0003 OG0013 OG0027 OG003

AEs leading to discontinuation

Title	Measurements
	OG0000 OG0010 OG0020 OG003

Deaths

Title	Measurements
	OG0000 OG0011 OG0022 OG003

Primary

Number of Participants With Abnormal Hepatic Test Values

Number of participants experiencing abnormal hepatic function, as measured by different parameters.

ALT = Alanine aminotransferase AST = Aspartate aminotransferase ULN = Upper Limit of Normal

All treated participants

Posted

Count of Participants

Participants

From first dose to 30 days following last dose (up to approximately 29 months)

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG010	Part 2 Schedule A	BMS-986158 administered at 4.5 mg QD for 5 consecutive days, followed by a 2 days resting period, for a total of 10 doses. Then, BMS-986158 is administered at the 3.75 mg dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle

Units	Counts
Participants	OG0005 OG0014 OG00213 OG003

Title

Denominators

Categories

ALT OR AST > 3XULN

Title	Measurements
	OG0002 OG0011 OG0022 OG003

Secondary

Best Overall Response (BOR)

BOR, as assessed by the investigator, is defined as the best response designation, recorded between the dates of first dose and the date of first objectively documented progression (per RECIST v1.1 for solid tumors, Lugano 2014 criteria for hematologic malignancies or PCWG3 for prostate cancer) or the date of subsequent therapy, whichever occurs first.

All treated participants

Posted

Count of Participants

Participants

From first dose to date of first documented progression or subsequent therapy (up to approximately 28 months)

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG010	Part 2 Schedule A	BMS-986158 administered at 4.5 mg QD for 5 consecutive days, followed by a 2 days resting period, for a total of 10 doses. Then, BMS-986158 is administered at the 3.75 mg dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle

Units	Counts
Participants	OG0005 OG0014 OG00213 OG003

Title

Denominators

Categories

Complete Response

Title	Measurements
	OG0000 OG0010 OG0020 OG003

Secondary

Objective Response Rate (ORR)

ORR is defined as the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR)

All treated participants

Posted

Number

95% Confidence Interval

Percent of Participants

From first dose to date of first documented progression or subsequent therapy (up to approximately 28 months)

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG010	Part 2 Schedule A	BMS-986158 administered at 4.5 mg QD for 5 consecutive days, followed by a 2 days resting period, for a total of 10 doses. Then, BMS-986158 is administered at the 3.75 mg dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle

Units	Counts
Participants	OG0005 OG0014 OG00213 OG003

Title

Denominators

Categories

Title	Measurements
	OG0000(0.0 to 52.2) OG0010(0.0 to 60.2) OG0020(0.0 to 24.7) OG003

Secondary

Duration of Response (DOR)

DOR is defined as the time between the date of first response and the date of the first objectively documented disease progression (as determined by RECIST v1.1 for solid tumors, Lugano 2014 criteria for hematologic malignancies, or PCWG3 (including PSA assessments) for prostate cancer [CRPC or NEPC]), or death due to any cause, whichever occurs first.

All participants who achieved a Complete Response (CR) or Partial Response (PR)

Posted

Mean

Standard Deviation

Weeks

From date of first response to date of first objectively documented disease progression or death (up to approximately 42 weeks)

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG010	Part 2 Schedule A	BMS-986158 administered at 4.5 mg QD for 5 consecutive days, followed by a 2 days resting period, for a total of 10 doses. Then, BMS-986158 is administered at the 3.75 mg dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle

Units	Counts
Participants	OG0000 OG0010 OG0020 OG003

Title

Denominators

Categories

Title	Measurements
	OG00422.3± NAOnly 1 participant was analyzed in this cohort OG01042.4± NAOnly 1 participant was analyzed in this cohort

Secondary

Progression Free Survival (PFS)

PFS is defined as the time from the first dose of study medication to the date of the first objective documentation of tumor progression or death due to any cause.

All treated participants.

Posted

Median

95% Confidence Interval

Weeks

From first dose to date of first objectively documented disease progression or death (up to approximately 28 months)

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG010	Part 2 Schedule A	BMS-986158 administered at 4.5 mg QD for 5 consecutive days, followed by a 2 days resting period, for a total of 10 doses. Then, BMS-986158 is administered at the 3.75 mg dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle

Units	Counts
Participants	OG0005 OG0014 OG00213 OG003

Title

Denominators

Categories

Title	Measurements
	OG0004.57(2.86 to 14.43) OG0019.71(6.57 to 25.43) OG0027.57(3.57 to 15.86) OG003

Secondary

Progression Free Survival Rate (PFSR)

PFSR is defined as the percentage of participants who remain progression free and surviving at the specified timepoints (12 weeks, 24 weeks, and 48 weeks).

Reported values are estimates derived from Kaplan-Meier analyses

All treated participants.

Posted

Number

95% Confidence Interval

Percent of participants

From first dose to 12 weeks, to 24 weeks, and to 48 weeks after first dose

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG010	Part 2 Schedule A	BMS-986158 administered at 4.5 mg QD for 5 consecutive days, followed by a 2 days resting period, for a total of 10 doses. Then, BMS-986158 is administered at the 3.75 mg dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle

Units	Counts
Participants	OG0005 OG0014 OG00213 OG003

Title

Denominators

Categories

12 weeks

Title	Measurements
	OG00020.0(0.8 to 58.2) OG00133.3(0.9 to 77.4) OG00227.3(6.5 to 53.9) OG003

Secondary

Maximum Observed Plasma Concentration (Cmax) - Single Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485

All treated participants with available measurements

Posted

Geometric Mean

Geometric Coefficient of Variation

ng/mL

From drug administration in Cycle 1 Day 1 to 168 hours post drug administration

ID	Title	Description
OG000	BMS-986158 0.75 mg	All participants treated with BMS-986158 at 0.75 mg dose, regardless of the dosing schedule.
OG001	BMS-986158 1.25 mg	All participants treated with BMS-986158 at 1.25 mg dose, regardless of the dosing schedule.
OG002	BMS-986158 2 mg	All participants treated with BMS-986158 at 2 mg dose, regardless of the dosing schedule.
OG003	BMS-986158 3 mg	All participants treated with BMS-986158 at 3 mg dose, regardless of the dosing schedule.
OG004	BMS-986158 4.5 mg	All participants treated with BMS-986158 at 4.5 mg dose, regardless of the dosing schedule.

Units	Counts
Participants	OG0005 OG0013 OG00216 OG003

Title	Denominators	Categories
Parent BMS-986158	ParticipantsOG0005 ParticipantsOG0013 ParticipantsOG00216 ParticipantsOG003

Secondary

Time of Maximum Observed Plasma Concentration (Tmax) - Single Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485

All treated participants with available measurements

Posted

Median

Full Range

Hours

From drug administration in Cycle 1 Day 1 to 168 hours post drug administration

ID	Title	Description
OG000	BMS-986158 0.75 mg	All participants treated with BMS-986158 at 0.75 mg dose, regardless of the dosing schedule.
OG001	BMS-986158 1.25 mg	All participants treated with BMS-986158 at 1.25 mg dose, regardless of the dosing schedule.
OG002	BMS-986158 2 mg	All participants treated with BMS-986158 at 2 mg dose, regardless of the dosing schedule.
OG003	BMS-986158 3 mg	All participants treated with BMS-986158 at 3 mg dose, regardless of the dosing schedule.
OG004	BMS-986158 4.5 mg	All participants treated with BMS-986158 at 4.5 mg dose, regardless of the dosing schedule.

Units	Counts
Participants	OG0005 OG0013 OG00216 OG003

Title	Denominators	Categories
Parent BMS-986158	ParticipantsOG0005 ParticipantsOG0013 ParticipantsOG00216 ParticipantsOG003

Secondary

Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Single Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485

All treated participants with available measurements

Posted

Geometric Mean

Geometric Coefficient of Variation

hr*ng/mL

From drug administration in Cycle 1 Day 1 to 168 hours post drug administration

ID	Title	Description
OG000	BMS-986158 0.75 mg	All participants treated with BMS-986158 at 0.75 mg dose, regardless of the dosing schedule.
OG001	BMS-986158 1.25 mg	All participants treated with BMS-986158 at 1.25 mg dose, regardless of the dosing schedule.
OG002	BMS-986158 2 mg	All participants treated with BMS-986158 at 2 mg dose, regardless of the dosing schedule.
OG003	BMS-986158 3 mg	All participants treated with BMS-986158 at 3 mg dose, regardless of the dosing schedule.
OG004	BMS-986158 4.5 mg	All participants treated with BMS-986158 at 4.5 mg dose, regardless of the dosing schedule.

Units	Counts
Participants	OG0005 OG0013 OG00216 OG003

Title	Denominators	Categories
Parent BMS-986158	ParticipantsOG0005 ParticipantsOG0013 ParticipantsOG00216 ParticipantsOG003

Secondary

Apparent Terminal Phase Half-Life (T-HALF) - Single Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485

All treated participants with available measurements

Posted

Mean

Standard Deviation

From drug administration in Cycle 1 Day 1 to 168 hours post drug administration

ID	Title	Description
OG000	BMS-986158 0.75 mg	All participants treated with BMS-986158 at 0.75 mg dose, regardless of the dosing schedule.
OG001	BMS-986158 1.25 mg	All participants treated with BMS-986158 at 1.25 mg dose, regardless of the dosing schedule.
OG002	BMS-986158 2 mg	All participants treated with BMS-986158 at 2 mg dose, regardless of the dosing schedule.
OG003	BMS-986158 3 mg	All participants treated with BMS-986158 at 3 mg dose, regardless of the dosing schedule.
OG004	BMS-986158 4.5 mg	All participants treated with BMS-986158 at 4.5 mg dose, regardless of the dosing schedule.

Units	Counts
Participants	OG0004 OG0013 OG00211 OG003

Title	Denominators	Categories
Parent BMS-986158	ParticipantsOG0004 ParticipantsOG0013 ParticipantsOG00211 ParticipantsOG003

Secondary

Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) - Single Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485

All treated participants with available measurements

Posted

Geometric Mean

Geometric Coefficient of Variation

hr*ng/mL

From drug administration in Cycle 1 Day 1 to 168 hours post drug administration

ID	Title	Description
OG000	BMS-986158 0.75 mg	All participants treated with BMS-986158 at 0.75 mg dose, regardless of the dosing schedule.
OG001	BMS-986158 1.25 mg	All participants treated with BMS-986158 at 1.25 mg dose, regardless of the dosing schedule.
OG002	BMS-986158 2 mg	All participants treated with BMS-986158 at 2 mg dose, regardless of the dosing schedule.
OG003	BMS-986158 3 mg	All participants treated with BMS-986158 at 3 mg dose, regardless of the dosing schedule.
OG004	BMS-986158 4.5 mg	All participants treated with BMS-986158 at 4.5 mg dose, regardless of the dosing schedule.

Units	Counts
Participants	OG0004 OG0013 OG00211 OG003

Title	Denominators	Categories
Parent BMS-986158	ParticipantsOG0004 ParticipantsOG0013 ParticipantsOG00211 ParticipantsOG003

Secondary

Apparent Total Body Clearance (CLT/F) - Single Dose Administration

Values are reported only for the parent BMS-986158

All treated participants with available measurements

Posted

Geometric Mean

Geometric Coefficient of Variation

mL/min

From drug administration in Cycle 1 Day 1 to 168 hours post drug administration

ID	Title	Description
OG000	BMS-986158 0.75 mg	All participants treated with BMS-986158 at 0.75 mg dose, regardless of the dosing schedule.
OG001	BMS-986158 1.25 mg	All participants treated with BMS-986158 at 1.25 mg dose, regardless of the dosing schedule.
OG002	BMS-986158 2 mg	All participants treated with BMS-986158 at 2 mg dose, regardless of the dosing schedule.
OG003	BMS-986158 3 mg	All participants treated with BMS-986158 at 3 mg dose, regardless of the dosing schedule.
OG004	BMS-986158 4.5 mg	All participants treated with BMS-986158 at 4.5 mg dose, regardless of the dosing schedule.

Units	Counts
Participants	OG0005 OG0013 OG00216 OG003

Title

Denominators

Categories

Title	Measurements
	OG0005.04± 17 OG0012.97± 18 OG0023.41± 56 OG003

Secondary

Apparent Volume of Distribution of Terminal Phase (Vz/F) - Single Dose Administration

Values are reported only for the parent BMS-986158

All treated participants with available measurements

Posted

Geometric Mean

Geometric Coefficient of Variation

Liters

From drug administration in Cycle 1 Day 1 to 168 hours post drug administration

ID	Title	Description
OG000	BMS-986158 0.75 mg	All participants treated with BMS-986158 at 0.75 mg dose, regardless of the dosing schedule.
OG001	BMS-986158 1.25 mg	All participants treated with BMS-986158 at 1.25 mg dose, regardless of the dosing schedule.
OG002	BMS-986158 2 mg	All participants treated with BMS-986158 at 2 mg dose, regardless of the dosing schedule.
OG003	BMS-986158 3 mg	All participants treated with BMS-986158 at 3 mg dose, regardless of the dosing schedule.
OG004	BMS-986158 4.5 mg	All participants treated with BMS-986158 at 4.5 mg dose, regardless of the dosing schedule.

Units	Counts
Participants	OG0004 OG0013 OG00211 OG003

Title

Denominators

Categories

Title	Measurements
	OG00014.7± 21 OG00112.5± 18 OG00214.8± 27 OG003

Secondary

Maximum Observed Plasma Concentration (Cmax) - Multiple Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485.

Values are also reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)

All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Posted

Geometric Mean

Geometric Coefficient of Variation

ng/mL

From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle

Units	Counts
Participants	OG0005 OG0014 OG0029 OG003

Title	Denominators	Categories
Parent BMS-986158 - Cycle 1 Day 1	ParticipantsOG0005 ParticipantsOG0013 ParticipantsOG0029 ParticipantsOG003

Secondary

Time to Maximum Observed Plasma Concentration (Tmax) - Multiple Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485.

Values are also reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)

All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Posted

Median

Full Range

Hours

From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle

Units	Counts
Participants	OG0005 OG0014 OG0029 OG003

Title	Denominators	Categories
Parent BMS-986158 - Cycle 1 day 1	ParticipantsOG0005 ParticipantsOG0013 ParticipantsOG0029 ParticipantsOG003

Secondary

Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) - Multiple Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485.

Values are also reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)

All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Posted

Geometric Mean

Geometric Coefficient of Variation

h*ng/mL

From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle

Units	Counts
Participants	OG0005 OG0014 OG0029 OG003

Title	Denominators	Categories
Parent BMS-986158 - Cycle 1 day 1	ParticipantsOG0005 ParticipantsOG0013 ParticipantsOG0029 ParticipantsOG003

Secondary

Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) - Multiple Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485.

Values are also reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)

All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Posted

Geometric Mean

Geometric Coefficient of Variation

h*ng/mL

From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle

Units	Counts
Participants	OG0005 OG0013 OG0029 OG003

Title	Denominators	Categories
Parent BMS-986158 - Cycle 1 day 1	ParticipantsOG0005 ParticipantsOG0013 ParticipantsOG0029 ParticipantsOG003

Secondary

Minimum Observed Concentration Within a Dosing Interval (Cmin) - Multiple Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485.

Values are reported only for the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)

All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Posted

Geometric Mean

Geometric Coefficient of Variation

ng/mL

From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle

Units	Counts
Participants	OG0004 OG0014 OG0027 OG003

Title	Denominators	Categories
Parent BMS-986158 - Latest timepoint	ParticipantsOG0004 ParticipantsOG0014 ParticipantsOG0027 ParticipantsOG003

Secondary

Concentration at the End of Dosing Interval (C24) - Multiple Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485.

Values are also reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)

All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Posted

Geometric Mean

Geometric Coefficient of Variation

ng/mL

From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle

Units	Counts
Participants	OG0005 OG0014 OG0029 OG003

Title	Denominators	Categories
Parent BMS-986158 - Cycle 1 Day 1	ParticipantsOG0005 ParticipantsOG0013 ParticipantsOG0029 ParticipantsOG003

Secondary

Trough Observed Plasma Concentration (Ctrough) - Multiple Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485.

Values are also reported separately for the first and last collection

All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Posted

Geometric Mean

Geometric Coefficient of Variation

ng/mL

From Cycle (C)2 Day (D)2 to C2D5 (Schedule A) or from C2D14 to C4D8 (Schedule B) or from C2D7 to C8D8 (Schedule C)

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle

Units	Counts
Participants	OG0004 OG0013 OG0024 OG003

Title	Denominators	Categories
Parent BMS-986158 - First collection	ParticipantsOG0004 ParticipantsOG0013 ParticipantsOG0024 ParticipantsOG003

Secondary

Accumulation Index (AI) - Multiple Dose Administration

AI is defined as the ratio of an exposure measure at steady-state to that after the first dose. Reported exposure measures include Cmax, C24 and AUC24.

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485.

All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Posted

Geometric Mean

Geometric Coefficient of Variation

Ratio

Cycle 2 Day 5 (Schedule A) or Cycle 2 Day 14 (Schedule B) or Cycle 2 Day 7 (Schedule C)

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle

Units	Counts
Participants	OG0004 OG0013 OG0027 OG003

Title	Denominators	Categories
Parent BMS-986158 - Cmax	ParticipantsOG0004 ParticipantsOG0013 ParticipantsOG0027 ParticipantsOG003

Secondary

Effective Elimination Half-Life (Effective T-HALF) - Multiple Dose Administration

Values are reported separately for the parent BMS-986158 and its metabolite BMT-161485.

All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Posted

Mean

Standard Deviation

Hours

Cycle 2 Day 5 (Schedule A) or Cycle 2 Day 14 (Schedule B) or Cycle 2 Day 7 (Schedule C)

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle

Units	Counts
Participants	OG0003 OG0010 OG0020 OG003

Title	Denominators	Categories
Parent BMS-986158	ParticipantsOG0003 ParticipantsOG0010 ParticipantsOG0020 ParticipantsOG003

Secondary

Ratio of Metabolite (BMT-161485) Maximum Observed Plasma Concentration (Cmax) to Parent (BMS-986158) Cmax - Multiple Dose Administration

Values are reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)

All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Posted

Mean

Standard Deviation

Ratio

From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle

Units	Counts
Participants	OG0005 OG0014 OG0028 OG003

Title	Denominators	Categories
Cycle 1 Day 1	ParticipantsOG0005 ParticipantsOG0013 ParticipantsOG0028 ParticipantsOG003

Secondary

Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) to Parent (BMS-986158) AUC(0-T) - Multiple Dose Administration

Values are reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)

All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Posted

Mean

Standard Deviation

Ratio

From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle

Units	Counts
Participants	OG0005 OG0014 OG0028 OG003

Title	Denominators	Categories
Cycle 1 Day 1	ParticipantsOG0005 ParticipantsOG0013 ParticipantsOG0028 ParticipantsOG003

Secondary

Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) to Parent (BMS-986158) AUC(INF) - Multiple Dose Administration

All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Posted

Mean

Standard Deviation

Ratio

Cycle 1 Day 1

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle

Units	Counts
Participants	OG0001 OG0013 OG0024 OG003

Title

Denominators

Categories

Title	Measurements
	OG0000.177± NAOnly 1 participant analyzed in this cohort OG0010.131± 0.0426 OG0020.120± 0.0286

Secondary

Ratio of Metabolite (BMT-161485) Area Under the Plasma Concentration-Time Curve in One Dosing Interval (AUC(0-24)) to Parent (BMS-986158) AUC(0-24) - Multiple Dose Administration

Values are reported separately for Cycle 1 Day 1 and the latest collection timepoint available (Cycle 2 Day 5 for Schedule A, Cycle 2 day 14 for Schedule B, Cycle 2 Day 7 for Schedule C)

All treated participants with available measurements. PK data not collected for the participant in Part 2 Schedule A cohort

Posted

Mean

Standard Deviation

Ratio

From Cycle 1 Day 1 to Cycle 2 Day 5 (Schedule A) or to Cycle 2 Day 14 (Schedule B) or to Cycle 2 Day 7 (Schedule C)

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle

Units	Counts
Participants	OG0005 OG0013 OG0028 OG003

Title	Denominators	Categories
Cycle 1 Day 1	ParticipantsOG0005 ParticipantsOG0013 ParticipantsOG0028 ParticipantsOG003

Secondary

Change From Baseline in Electrocardiogram Parameter QTcF

QT Interval corrected for Fridericia's Formula. Change from baseline is calculated from pre-dose at the indicated timepoints.

All treated participants with available measurements at the indicated timepoints. PK data not collected for the participant in Part 2 Schedule A cohort

Posted

Mean

Standard Deviation

msec

From Cycle 1 Day 1 to last dosing day in Cycle 2 (C2D8 for Schedule A, C2D14 for Schedule B, C2D7 for Schedule C).

ID	Title	Description
OG000	Part 1 Schedule A - BMS-986158 0.75 mg	Single dose of BMS-986158 at 0.75 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG001	Part 1 Schedule A - BMS-986158 1.25 mg	Single dose of BMS-986158 at 1.25 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG002	Part 1 Schedule A - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG003	Part 1 Schedule A - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG004	Part 1 Schedule A - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 5 consecutive days, followed by a 2 days rest period, on a 28 days cycle
OG005	Part 1 Schedule B - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG006	Part 1 Schedule B - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 14 consecutive days, followed by a 7 days rest period, on a 21 days cycle
OG007	Part 1 Schedule C - BMS-986158 2 mg	Single dose of BMS-986158 at 2 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG008	Part 1 Schedule C - BMS-986158 3 mg	Single dose of BMS-986158 at 3 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle
OG009	Part 1 Schedule C - BMS-986158 4.5 mg	Single dose of BMS-986158 at 4.5 mg. Approximately 7 days later, BMS-986158 is administered at the same dose QD for 7 consecutive days, followed by a 14 days rest period, on a 21 days cycle

Units	Counts
Participants	OG0004 OG0011 OG0029 OG003

Title

Denominators

Categories

Title	Measurements
	OG000-6.8± 11.63 OG001-5.3± NAOnly 1 participant analyzed in this cohort OG002-3.3± 22.48

24 weeks

Title	Measurements
	OG0000.0(NA to NA)Insufficient number of events OG00133.3(0.9 to 77.4) OG0029.1(0.5 to 33.3) OG00311.1(0.6 to 38.8) OG00430.0(7.1 to 57.8) OG00550.0(5.8 to 84.5) OG00633.3(0.9 to 77.4) OG0070.0(NA to NA)Insufficient number of events OG00818.3(2.9 to 44.4) OG0090.0(NA to NA)Insufficient number of events OG010100.0(100.0 to 100.0)

48 weeks

Title

Measurements

OG0000.0(NA to NA)Insufficient number of events
OG0010.0(NA to NA)Insufficient number of events
OG0020.0(NA to NA)Insufficient number of events
OG0030.0(NA to NA)Insufficient number of events
OG0040.0(NA to NA)Insufficient number of events
OG00525.0(0.9 to 66.5)
OG0060.0(NA to NA)Insufficient number of events
OG0070.0(NA to NA)Insufficient number of events
OG0089.2(0.5 to 33.5)
OG0090.0(NA to NA)Insufficient number of events
OG010100.0(100.0 to 100.0)

Metabolite BMT-161485

- ParticipantsOG0005
- ParticipantsOG0013
- ParticipantsOG00215
- ParticipantsOG00324
- ParticipantsOG00417

Title	Measurements
	OG00024.0(2.55 to 24.2) OG0012.00(2.00 to 24.0) OG0026.00(1.00 to 72.0) OG003

Metabolite BMT-161485

- ParticipantsOG0001
- ParticipantsOG0013
- ParticipantsOG0028
- ParticipantsOG00311
- ParticipantsOG00410

Title	Measurements
	OG00035.3± NAOnly 1 participants analyzed in this cohort OG00150.8± 6.26 OG00248.8± 18.78 OG003

Metabolite BMT-161485

- ParticipantsOG0001
- ParticipantsOG0013
- ParticipantsOG0028
- ParticipantsOG00311
- ParticipantsOG00410

Title	Measurements
	OG000409± NAOnly 1 participants analyzed in this cohort OG001892± 13 OG002944± 73 OG003

Parent BMS-986158 - Latest timepoint

- ParticipantsOG0004
- ParticipantsOG0014
- ParticipantsOG0027
- ParticipantsOG0038
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG000136± 43 OG001284± 16 OG002442± 29 OG003

Metabolite BMT-161485 - Cycle 1 Day 1

- ParticipantsOG0005
- ParticipantsOG0013
- ParticipantsOG0028
- ParticipantsOG0039
- ParticipantsOG00410
- ParticipantsOG0051
- ParticipantsOG0064
- ParticipantsOG0076
- ParticipantsOG00811
- ParticipantsOG0097

Title	Measurements
	OG0005.00± 30 OG00110.0± 29 OG00216.9± 32 OG003

Metabolite BMT-161485 -Latest timepoint

- ParticipantsOG0003
- ParticipantsOG0014
- ParticipantsOG0027
- ParticipantsOG0038
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG00025.8± 82 OG00131.0± 25 OG00249.4± 46 OG003

Title	Measurements
	OG0004.00(2.00 to 4.02) OG0011.00(1.00 to 2.00) OG0022.00(1.00 to 4.03) OG0032.00(0.983 to 6.15) OG0042.04(1.00 to 4.03) OG0051.00(1.00 to 1.00) OG0061.03(1.00 to 4.03) OG0071.00(0.500 to 2.03) OG0081.00(0.500 to 2.02) OG0092.02(1.00 to 4.00)

Parent BMS-986158 - Latest timepoint

- ParticipantsOG0004
- ParticipantsOG0014
- ParticipantsOG0027
- ParticipantsOG0038
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG0003.14(2.00 to 6.05) OG0011.50(0.500 to 2.00) OG0022.00(0.500 to 4.02) OG003

Metabolite BMT-161485 - Cycle 1 Day 1

- ParticipantsOG0005
- ParticipantsOG0013
- ParticipantsOG0028
- ParticipantsOG0039
- ParticipantsOG00410
- ParticipantsOG0051
- ParticipantsOG0064
- ParticipantsOG0076
- ParticipantsOG00811
- ParticipantsOG0097

Title	Measurements
	OG00024.0(2.55 to 24.2) OG0012.00(2.00 to 24.0) OG0025.08(2.00 to 72.0) OG003

Metabolite BMT-161485 -Latest timepoint

- ParticipantsOG0003
- ParticipantsOG0014
- ParticipantsOG0027
- ParticipantsOG0038
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG00024.0(24.0 to 24.0) OG0014.00(1.50 to 6.00) OG0022.07(0 to 4.02) OG003

Title	Measurements
	OG0002150± 15 OG0016372± 14 OG0028564± 48 OG00310452± 50 OG00419124± 46 OG0055202± NAOnly 1 participant analyzed in this cohort OG00625852± 41 OG00710931± 43 OG00811493± 54 OG00917220± 84

Parent BMS-986158 - Latest timepoint

- ParticipantsOG0004
- ParticipantsOG0014
- ParticipantsOG0027
- ParticipantsOG0038
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG0003449± 93 OG0014961± 73 OG0027612± 71 OG003

Metabolite BMT-161485 - Cycle 1 day 1

- ParticipantsOG0005
- ParticipantsOG0013
- ParticipantsOG0028
- ParticipantsOG0039
- ParticipantsOG00410
- ParticipantsOG0051
- ParticipantsOG0064
- ParticipantsOG0076
- ParticipantsOG00811
- ParticipantsOG0097

Title	Measurements
	OG000314± 32 OG001790± 14 OG002992± 65 OG003

Metabolite BMT-161485 -Latest timepoint

- ParticipantsOG0003
- ParticipantsOG0014
- ParticipantsOG0027
- ParticipantsOG0038
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG0001474± 89 OG001691± 73 OG0021110± 89 OG003

Parent BMS-986158 - Latest timepoint

- ParticipantsOG0003
- ParticipantsOG0011
- ParticipantsOG0020
- ParticipantsOG0037
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG0002716± 51 OG0013852± NAOnly 1 participant analyzed in this cohort OG0039817± 56 OG004

Metabolite BMT-161485 - Cycle 1 Day 1

- ParticipantsOG0005
- ParticipantsOG0013
- ParticipantsOG0028
- ParticipantsOG0039
- ParticipantsOG00410
- ParticipantsOG0051
- ParticipantsOG0064
- ParticipantsOG0076
- ParticipantsOG00811
- ParticipantsOG0097

Title	Measurements
	OG00098.2± 34 OG001188± 11 OG002290± 22 OG003

Metabolite BMT-161485 -Latest timepoint

- ParticipantsOG0003
- ParticipantsOG0011
- ParticipantsOG0020
- ParticipantsOG0037
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG000550± 81 OG001500± NAOnly 1 participant analyzed in this cohort OG0031746± 64 OG004

Title	Measurements
	OG00073.7± 45 OG001141± 17 OG002208± 53 OG003227± 76 OG004428± 41 OG00585.1± NAOnly 1 participant analyzed in this cohort OG006435± NAOnly 1 participant analyzed in this cohort OG007270± 42 OG008238± 94 OG009253± 125

Metabolite BMT-161485 -Latest timepoint

- ParticipantsOG0003
- ParticipantsOG0014
- ParticipantsOG0027
- ParticipantsOG0038
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG00016.4± 91 OG00122.3± 22 OG00233.7± 55 OG003

Parent BMS-986158 - Latest timepoint

- ParticipantsOG0003
- ParticipantsOG0011
- ParticipantsOG0020
- ParticipantsOG0037
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG00087.9± 63 OG001116± NAOnly 1 participant analyzed in this cohort OG003280± 64 OG004

Metabolite BMT-161485 - Cycle 1 Day 1

- ParticipantsOG0005
- ParticipantsOG0013
- ParticipantsOG0028
- ParticipantsOG0039
- ParticipantsOG00410
- ParticipantsOG0051
- ParticipantsOG0064
- ParticipantsOG0076
- ParticipantsOG00811
- ParticipantsOG0097

Title	Measurements
	OG0004.85± 29 OG0017.92± 8 OG00212.0± 37 OG003

Metabolite BMT-161485 -Latest timepoint

- ParticipantsOG0003
- ParticipantsOG0014
- ParticipantsOG0027
- ParticipantsOG0038
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG00016.4± 91 OG00122.3± 22 OG00233.7± 55 OG003

Title	Measurements
	OG00035.7± 25 OG00179.6± 10 OG002142± 51 OG003138± 48 OG004257± 27 OG005109± NAOnly 1 participant analyzed in this cohort OG006435± NAOnly 1 participant analyzed in this cohort OG007242± 58 OG008282± 98 OG009284± 119

Parent BMS-986158 -Last collection

- ParticipantsOG0003
- ParticipantsOG0011
- ParticipantsOG0020
- ParticipantsOG0037
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0060
- ParticipantsOG0071
- ParticipantsOG0081
- ParticipantsOG0090

Title	Measurements
	OG00087.9± 63 OG001116± NAOnly 1 participant analyzed in this cohort OG003280± 64 OG004

Metabolite BMT-161485 - First collection

- ParticipantsOG0004
- ParticipantsOG0013
- ParticipantsOG0024
- ParticipantsOG0038
- ParticipantsOG0049
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0073
- ParticipantsOG0086
- ParticipantsOG0097

Title	Measurements
	OG0007.78± 36 OG0019.42± 19 OG00211.4± 51 OG003

Metabolite BMT-161485 - Last collection

- ParticipantsOG0003
- ParticipantsOG0011
- ParticipantsOG0020
- ParticipantsOG0037
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0060
- ParticipantsOG0071
- ParticipantsOG0081
- ParticipantsOG0090

Title	Measurements
	OG00025.8± 82 OG00120.1± NAOnly 1 participant analyzed in this cohort OG00365.8± 63 OG004

Title	Measurements
	OG0001.89± 20 OG0011.72± 20 OG0021.76± 34 OG0031.94± 42 OG0041.79± 29 OG0051.35± NAOnly 1 participant analyzed in this cohort OG0062.37± NAOnly 1 participant analyzed in this cohort OG0071.65± 13 OG0081.50± 38 OG0091.59± 47

Parent BMS-986158 - C24

- ParticipantsOG0003
- ParticipantsOG0010
- ParticipantsOG0020
- ParticipantsOG0037
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG0002.58± 51 OG0031.79± 38 OG0042.24± 29 OG005

Parent BMS-986158 - AUC24

- ParticipantsOG0003
- ParticipantsOG0010
- ParticipantsOG0020
- ParticipantsOG0037
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG0002.60± 35 OG0031.95± 38 OG0042.15± 23 OG005

Metabolite BMT-161485 - Cmax

- ParticipantsOG0003
- ParticipantsOG0013
- ParticipantsOG0027
- ParticipantsOG0038
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG0004.53± 54 OG0013.44± 38 OG0022.91± 27 OG003

Metabolite BMT-161485 - C24

- ParticipantsOG0003
- ParticipantsOG0010
- ParticipantsOG0020
- ParticipantsOG0037
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG0004.63± 58 OG0033.18± 38 OG0044.33± 39 OG005

Metabolite BMT-161485 - AUC24

- ParticipantsOG0003
- ParticipantsOG0010
- ParticipantsOG0020
- ParticipantsOG0037
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG0005.06± 45 OG0034.20± 55 OG0045.03± 34 OG005

Title	Measurements
	OG00036.0± 15.99 OG00325.7± 14.86 OG00427.3± 8.72 OG00514.4± NAOnly 1 participant analyzed in this cohort OG00637.3± NAOnly 1 participant analyzed in this cohort OG00731.6± 10.48 OG00827.3± 15.15 OG00927.6± 19.11

Metabolite BMT-161485

- ParticipantsOG0003
- ParticipantsOG0010
- ParticipantsOG0020
- ParticipantsOG0037
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG00080.9± 40.42 OG00372.1± 47.11 OG00480.4± 29.59 OG005

Title	Measurements
	OG0000.073± 0.0104 OG0010.057± 0.0052 OG0020.068± 0.0204 OG0030.078± 0.0268 OG0040.068± 0.0303 OG0050.066± NAOnly 1 participant analyzed in this cohort OG0060.059± 0.0247 OG0070.077± 0.0373 OG0080.056± 0.0187 OG0090.083± 0.0209

Latest timepoint

- ParticipantsOG0003
- ParticipantsOG0014
- ParticipantsOG0027
- ParticipantsOG0038
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG0000.179± 0.0726 OG0010.112± 0.0329 OG0020.115± 0.0290 OG003

Title	Measurements
	OG0000.154± 0.0504 OG0010.127± 0.0369 OG0020.125± 0.0262 OG0030.152± 0.0572 OG0040.151± 0.0558 OG0050.081± NAOnly 1 participant analyzed in this cohort OG0060.099± 0.0279 OG0070.182± 0.0632 OG0080.114± 0.0473 OG0090.170± 0.0821

Latest timepoint

- ParticipantsOG0003
- ParticipantsOG0014
- ParticipantsOG0027
- ParticipantsOG0038
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG0000.247± 0.1000 OG0010.141± 0.0248 OG0020.150± 0.0377 OG003

Title	Measurements
	OG0000.099± 0.0290 OG0010.081± 0.0055 OG0020.086± 0.0208 OG0030.097± 0.0425 OG0040.087± 0.0347 OG0050.081± NAOnly 1 participant analyzed in this cohort OG0060.066± 0.0221 OG0070.102± 0.0178 OG0080.080± 0.0283 OG0090.108± 0.0445

Latest timepoint

- ParticipantsOG0003
- ParticipantsOG0011
- ParticipantsOG0020
- ParticipantsOG0037
- ParticipantsOG0048
- ParticipantsOG0051
- ParticipantsOG0061
- ParticipantsOG0075
- ParticipantsOG0088
- ParticipantsOG0097

Title	Measurements
	OG0000.213± 0.0786 OG0010.130± NAOnly 1 participant analyzed in this cohort OG0030.192± 0.0697 OG004